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1. INTRODUCTION {#dom13261-sec-0005}
===============

Type 2 diabetes (T2D) is characterized by a progressive worsening of glycaemic control, stemming from insulin resistance and gradual β‐cell failure.[1](#dom13261-bib-0001){ref-type="ref"}, [2](#dom13261-bib-0002){ref-type="ref"} After diagnosis, the management of diabetes typically involves recommendations to implement various lifestyle measures, together with the administration of oral antidiabetic drugs. Despite these recommendations, compliance with lifestyle recommendations[3](#dom13261-bib-0003){ref-type="ref"} and appropriate pharmacological treatment is low among patients with T2D.[4](#dom13261-bib-0004){ref-type="ref"} Consequently, glycaemic control often worsens, and insulin is frequently required to supplement the diminished endogenous secretory capacity.[1](#dom13261-bib-0001){ref-type="ref"}, [2](#dom13261-bib-0002){ref-type="ref"} The most common management approach is to initiate insulin therapy with once‐daily basal insulin,[5](#dom13261-bib-0005){ref-type="ref"} which has the following benefits: simplicity; low frequency of injections and blood glucose monitoring; low risk of hypoglycaemia; and good patient acceptability.[6](#dom13261-bib-0006){ref-type="ref"}, [7](#dom13261-bib-0007){ref-type="ref"} Although basal insulin helps regain fasting glycaemic control, prandial glucose excursions often remain unacceptably high, and the addition of 1 or more prandial insulin doses is usually required.[6](#dom13261-bib-0006){ref-type="ref"}, [8](#dom13261-bib-0008){ref-type="ref"} The need for insulin, whether initiation of basal insulin or intensification with bolus insulin, can be met with reluctance from both patients and their physicians.[9](#dom13261-bib-0009){ref-type="ref"}, [10](#dom13261-bib-0010){ref-type="ref"}, [11](#dom13261-bib-0011){ref-type="ref"} Intensification of insulin from basal alone to multiple daily injections is often resisted because of a perception that insulin regimens requiring multiple daily injections (particularly those using 2 types of insulin) and/or regular self‐measurement of blood glucose levels for dose adjustments are inconvenient or too complex to manage.[9](#dom13261-bib-0009){ref-type="ref"}, [10](#dom13261-bib-0010){ref-type="ref"}, [12](#dom13261-bib-0012){ref-type="ref"}, [13](#dom13261-bib-0013){ref-type="ref"} Patients may also be concerned about treatment‐emergent effects of insulin use, such as weight gain[14](#dom13261-bib-0014){ref-type="ref"}, [15](#dom13261-bib-0015){ref-type="ref"} or hypoglycaemia, the latter potentially posing a barrier to optimal insulin therapy because of patient fear generated by episodes of hypoglycaemia.[16](#dom13261-bib-0016){ref-type="ref"}, [17](#dom13261-bib-0017){ref-type="ref"} Physicians are also apprehensive of hypoglycaemia and, as a consequence, may refrain from or delay prescription of more intensive insulin regimens.[16](#dom13261-bib-0016){ref-type="ref"} Although most patients with T2D have a trajectory towards an intensification of their treatment, patients requiring initiation of basal insulin vary regarding their level of glycaemic control, duration of diabetes, body weight and acceptance of more complex treatment regimens. Considering this diversity, and the potential differences in insulin dose requirement and risk of hypoglycaemia, current treatment guidelines for T2D recommend that treatment is individualized according to a particular patient\'s needs.[5](#dom13261-bib-0005){ref-type="ref"} It is recommended that glycaemic targets and medications be selected after consideration of a patient\'s body weight/body mass index (BMI), age, duration of diabetes, risk of hypoglycaemia, attitude and expectations, and the presence of comorbidities.[5](#dom13261-bib-0005){ref-type="ref"}

One option for patients with T2D requiring intensified insulin management is a switch from basal insulin to premixed insulin containing both rapid‐ and longer‐acting components in a single injection. Although premixed insulins can improve patient adherence as fewer injections are required,[18](#dom13261-bib-0018){ref-type="ref"}, [19](#dom13261-bib-0019){ref-type="ref"} when administered once daily, 24‐hour basal coverage is not possible[20](#dom13261-bib-0020){ref-type="ref"}, [21](#dom13261-bib-0021){ref-type="ref"}, [22](#dom13261-bib-0022){ref-type="ref"}; as a consequence, glycaemic control is suboptimal for the majority of patients. In addition, some studies show that premixed insulins result in greater weight gain[13](#dom13261-bib-0013){ref-type="ref"} and higher rates of post‐meal and nocturnal hypoglycaemia compared with basal--bolus regimens,[23](#dom13261-bib-0023){ref-type="ref"} potentially limiting their use in some patients. Basal--bolus regimens can be considered for patients requiring a more physiological treatment, but patients must also be willing to accept the increased complexity of this regimen[5](#dom13261-bib-0005){ref-type="ref"} and be able to adjust their doses according to actual glucose values, anticipated food intake and physical activity.

"IDegAsp," insulin degludec (IDeg) and insulin aspart (IAsp), is the first soluble co‐formulation of basal (70% IDeg) and bolus (30% IAsp) insulin analogues, available in a single injection pen.[24](#dom13261-bib-0024){ref-type="ref"} IDegAsp provides flat and stable 24‐hour basal coverage that allows flexibility and once‐daily or twice‐daily use.[21](#dom13261-bib-0021){ref-type="ref"}, [25](#dom13261-bib-0025){ref-type="ref"}, [26](#dom13261-bib-0026){ref-type="ref"} The IDegAsp co‐formulation has been demonstrated to result in less interference in patients' day‐to‐day lives compared with intensified insulin therapy in a basal--bolus regimen, potentially improving treatment adherence and glycaemic control.[27](#dom13261-bib-0027){ref-type="ref"} Across the phase III clinical development programme, IDegAsp has been shown to provide effective glycaemic control and reduced rates of hypoglycaemia vs the premixed insulin biphasic insulin aspart 30 (BIAsp 30) in patients with T2D.[28](#dom13261-bib-0028){ref-type="ref"}, [29](#dom13261-bib-0029){ref-type="ref"}, [30](#dom13261-bib-0030){ref-type="ref"} With the advantages of IDegAsp having been proven vs some of the phase III trial comparators, it is of interest to investigate whether these benefits apply to patients with different baseline characteristics. As the phase III studies were of similar design (Table [1](#dom13261-tbl-0001){ref-type="table"} [27](#dom13261-bib-0027){ref-type="ref"}, [28](#dom13261-bib-0028){ref-type="ref"}, [29](#dom13261-bib-0029){ref-type="ref"}, [30](#dom13261-bib-0030){ref-type="ref"}, [31](#dom13261-bib-0031){ref-type="ref"}), it is possible to pool the data into a single post hoc analysis cohort to investigate the efficacy and safety of IDegAsp across a large population of patients.

###### 

Trial designs

  Study name                  START TWICE DAILY[28](#dom13261-bib-0028){ref-type="ref"}             INTENSIFY PREMIX[30](#dom13261-bib-0030){ref-type="ref"}                                           INTENSIFY ALL[29](#dom13261-bib-0029){ref-type="ref"}                                                SIMPLE vs STEP‐WISE TWICE DAILY[31](#dom13261-bib-0031){ref-type="ref"}                                                                      TWICE DAILY vs BASAL---BOLUS[27](#dom13261-bib-0027){ref-type="ref"}
  --------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Clinical trial number       NCT01513590                                                           NCT01009580                                                                                        NCT01059812                                                                                          NCT01680341                                                                                                                                  NCT01713530
  Trial duration, weeks       26                                                                    26                                                                                                 26                                                                                                   26                                                                                                                                           26
  Age, years                  ≥18                                                                   ≥18                                                                                                ≥18                                                                                                  ≥18                                                                                                                                          ≥18
  BMI, kg/m^2^                ≤40                                                                   ≤40                                                                                                ≤35                                                                                                  ≤40                                                                                                                                          ≤40
  HbA1c, mmol/mol             53.0--85.8                                                            53.0--85.8                                                                                         53.0--85.8                                                                                           53.0--85.8                                                                                                                                   53.0--85.8
  HbA1c, %                    7.0--10.0                                                             7.0--10.0                                                                                          7.0--10.0                                                                                            7.0--10.0                                                                                                                                    7.0--10.0
  Diabetes duration, months   T2D ≥ 6                                                               T2D ≥ 6                                                                                            T2D ≥ 6                                                                                              T2D ≥ 6                                                                                                                                      T2D ≥ 6
  Previous treatment          Insulin‐naïve treated with metformin ±1 OAD for ≥3 months             Previously treated with basal--bolus, premixed or self‐mixed insulin ± metformin ≥3 months         Asian patients previously treated with basal, premixed or self‐mixed insulin ± metformin ≥3 months   Currently treated with stable doses of IGlar U100 + ≤3 OADs for ≥3 months                                                                    Currently treated with basal insulin ± OADs for ≥3 months
  Trial treatments            IDegAsp twice daily + metformin vs BIAsp 30 twice daily + metformin   IDegAsp twice daily ± OADs vs BIAsp 30 twice daily ± OADs[a](#dom13261-note-0003){ref-type="fn"}   IDegAsp twice daily ± OADs vs BIAsp 30 twice daily ± OADs[a](#dom13261-note-0003){ref-type="fn"}     Simple vs step‐wise titration of IDegAsp twice daily ± OADs[b](#dom13261-note-0004){ref-type="fn"} [c](#dom13261-note-0005){ref-type="fn"}   IDegAsp twice daily ± OADs vs IDeg once daily + IAsp (2‐4 injections/day) ± OADs[b](#dom13261-note-0004){ref-type="fn"}

Abbreviations: BIAsp 30, biphasic insulin aspart 30; DPP‐4, dipeptidyl peptidase‐4; IAsp, insulin aspart; IDeg, insulin degludec; IDegAsp, insulin degludec/insulin aspart; IGlar U100, insulin glargine U100; OAD, oral antidiabetic drug; SMPG, self‐monitored plasma glucose; T2D, type 2 diabetes.

OADs used included ± metformin (NCT01059812) or metformin, DPP‐4 inhibitors and pioglitazone (NCT01009580).

OADs used during this trial included metformin, DPP‐4 inhibitors and alpha‐glucosidase inhibitors, while sulphonylureas or glinides were discontinued at randomization.

In this trial, 2 different titration regimens were compared: simple titration (following a single pre‐breakfast and pre‐dinner SMPG measurement) involving twice‐weekly up‐ or down‐titration by 2 U; and step‐wise titration (based on the lowest of 3 pre‐breakfast and 3 pre‐evening meal SMPG values) involving once‐weekly up‐ or downtitration of 2 to 8 U and 2 to 4 U, respectively.

2. MATERIALS AND METHODS {#dom13261-sec-0006}
========================

This post hoc pooled analysis of 5 phase III randomized, 26‐week, open‐label, treat‐to‐target trials aimed to assess whether IDegAsp twice daily had consistent safety and efficacy benefits in patients with different baseline characteristics (BMI, duration of diabetes and glycaemic control) when compared with BIAsp 30 twice daily or IDeg once daily + IAsp (2‐4 injections). Data were pooled from 5 clinical trials in the IDegAsp clinical development programme that included use of IDegAsp twice daily. All trials were registered with <http://www.clinicaltrials.gov> and conducted according to the Declaration of Helsinki[32](#dom13261-bib-0032){ref-type="ref"} and Good Clinical Practice Guidelines (as defined by the International Conference on Harmonisation).[33](#dom13261-bib-0033){ref-type="ref"} All participants provided prior written consent before the onset of trial‐related activities.

Trial designs have been reported previously and are shown in Table [1](#dom13261-tbl-0001){ref-type="table"},[27](#dom13261-bib-0027){ref-type="ref"}, [28](#dom13261-bib-0028){ref-type="ref"}, [29](#dom13261-bib-0029){ref-type="ref"}, [30](#dom13261-bib-0030){ref-type="ref"}, [31](#dom13261-bib-0031){ref-type="ref"} along with descriptions of individual study designs.

2.1. Pooled analysis {#dom13261-sec-0007}
--------------------

Comparators for the individual trials were pooled ("comparators" group) and included BIAsp 30 twice daily (*n* = 561) or IDeg once daily + IAsp (*n* = 136). Patient data for end‐of‐trial (EOT) HbA1c, confirmed hypoglycaemia, nocturnal confirmed hypoglycaemia and insulin dose were stratified according to: baseline HbA1c category: 53.0 to \<58.5 mmol/mol (7.0‐7.5% \[*n* = 263\]), ≥58.5 to \<69.4 mmol/mol (≥7.5 to \<8.5% \[*n* = 760\]), ≥69.4 to \<74.9 mmol/mol (≥8.5 to \<9.0% \[*n* = 309\]) or ≥74.9 mmol/mol (≥9.0% \[*n* = 476\]); duration of diabetes: ≤10 years (*n* = 728) or \>10 years (*n* = 1080); and BMI: ≤30 kg/m^2^ (*n* = 1000) or \>30 kg/m^2^ (*n* = 808). Patient data for EOT fasting plasma glucose (FPG) were stratified according to duration of diabetes and BMI as described above, and also by baseline FPG: \<5.5 mmol/L (\<99 mg/dL \[*n* = 170\]), ≥5.5 to \<7.0 mmol/L (≥99 to \<126 mg/dL \[*n* = 318\]), ≥7.0 to \<10.0 mmol/L (≥126 to \<180 mg/dL \[*n* = 787\]) or ≥10.0 mmol/L (≥180 mg/dL \[*n* = 523\]). Hypoglycaemic episodes were analysed using a negative binomial regression model with treatment, trial, sex, region, antidiabetic medicine at screening, and age as explanatory variables. Overall confirmed hypoglycaemia was classified as: "confirmed" (a plasma glucose measurement of \<3.1 mmol/L \[\<56.0 mg/dL\], or severe events requiring assistance from another person), plus "nocturnal confirmed" (any confirmed event between 12:01 [am]{.smallcaps} and 5:59 [am]{.smallcaps} inclusive). The EOT insulin doses (after 26 weeks) were analysed using an ANOVA method with treatment, trial, antidiabetic therapy at screening, sex and region as fixed factors, and age and baseline value as covariates. Pooled data and statistical analyses were for the full analysis set. Data reported are mean (SEM). Rates of hypoglycaemia were compared using rate ratios of IDegAsp vs comparator (per 100 patient‐years of exposure).

3. RESULTS {#dom13261-sec-0008}
==========

3.1. Baseline characteristics {#dom13261-sec-0009}
-----------------------------

A total of 1808 patients were included in the pooled analysis of the 5 randomized, 26‐week, treat‐to‐target, phase III clinical trials in patients with T2D. Baseline characteristics of patients enrolled in the trials are shown in Table S1 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}.[27](#dom13261-bib-0027){ref-type="ref"}, [28](#dom13261-bib-0028){ref-type="ref"}, [29](#dom13261-bib-0029){ref-type="ref"}, [30](#dom13261-bib-0030){ref-type="ref"}, [31](#dom13261-bib-0031){ref-type="ref"} There was no difference between the IDegAsp twice daily and comparator arms in the mean age of patients stratified by duration of diabetes (Figure S1 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}), nor was there any difference in mean EOT body weight of patients stratified by baseline BMI (Figure S2 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}).

3.2. Glycated haemoglobin {#dom13261-sec-0010}
-------------------------

In terms of EOT HbA1c, no significant differences were observed between IDegAsp twice daily and the comparator group when comparing across HbA1c categories (53.0‐\<58.5 mmol/mol, ≥58.5 to \<69.4 mmol/mol, ≥69.4 to \<74.9 mmol/mol and ≥74.9 mmol/mol; Figure [1](#dom13261-fig-0001){ref-type="fig"}A), duration of diabetes (≤10 and \>10 years; Figure [1](#dom13261-fig-0001){ref-type="fig"}B) and BMI groups (≤30 and \>30 kg/m^2^; Figure [1](#dom13261-fig-0001){ref-type="fig"}C) in these treat‐to‐target trials (Table S2 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}).

![Glycated haemoglobin (HbA1c) at end of trial stratified by: A, HbA1c category (mmol/mol); B, diabetes duration (years); and C, BMI (kg/m^2^). Data are mean (SEM) from full analysis set, LOCF. Comparators: biphasic insulin aspart 30 (BIAsp 30; NCT01009580, NCT01059812, NCT01513590), insulin degludec (IDeg) once daily + insulin aspart (IAsp; NCT01713530); Trial NCT01680341: insulin degludec/insulin aspart (IDegAsp) Simple and IDegAsp Step‐wise arms are considered within the IDegAsp group. EOT, end of trial](DOM-20-1585-g004){#dom13261-fig-0001}

3.3. Fasting plasma glucose {#dom13261-sec-0011}
---------------------------

Fasting plasma glucose at EOT (Figure [2](#dom13261-fig-0002){ref-type="fig"} and Table S2 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}) was numerically lower with IDegAsp twice daily than with comparators in patients in all baseline FPG categories, reaching statistical significance (*P* \< .001) in those with a baseline FPG level of ≥5.5 to \<7.0, ≥7.0 to \<10.0 or ≥10.0 mmol/L (Figure [2](#dom13261-fig-0002){ref-type="fig"}A). Significantly lower (*P* \< .0001) EOT FPG values were observed with IDegAsp twice daily vs comparators in patients with a duration of diabetes of ≤10 or \>10 years (Figure [2](#dom13261-fig-0002){ref-type="fig"}B) and in those with a BMI ≤30 or \>30 kg/m^2^ (Figure [2](#dom13261-fig-0002){ref-type="fig"}C).

![Fasting plasma glucose (FPG, mmol/L) at end of trial (EOT) by: A, baseline FPG (mmol/L), B, diabetes duration (years) and C, body mass index (BMI, kg/m^2^). Data are mean (SEM) from the full analysis set, LOCF. \*\**P* \< .001; \*\*\**P* \< .0001. Comparator: biphasic insulin aspart 30 (BIAsp 30; NCT01009580, NCT01059812, NCT01513590), insulin degludec (IDeg) once daily + insulin aspart (IAsp; NCT01713530). Trial NCT01680341: IDegAsp Simple and IDegAsp Step‐wise arms are considered within the IDegAsp group](DOM-20-1585-g003){#dom13261-fig-0002}

3.4. Hypoglycaemia {#dom13261-sec-0012}
------------------

Among all baseline characteristic and category groups, significantly lower rates of confirmed and nocturnal confirmed hypoglycaemia were observed with IDegAsp twice daily vs comparators. Rates of confirmed and nocturnal confirmed hypoglycaemia were significantly lower (*P* \< .05) with IDegAsp twice daily vs comparators in all 4 baseline HbA1c categories (53.0‐\<58.5 mmol/mol, ≥58.5 to \<69.4 mmol/mol, ≥69.4 to \<74.9 mmol/mol and ≥74.9 mmol/mol) with rate ratios of 0.66, 0.72, 0.68 and 0.74, respectively, for confirmed hypoglycaemia and 0.54, 0.43, 0.41 and 0.36 for nocturnal confirmed hypoglycaemia (Figures [3](#dom13261-fig-0003){ref-type="fig"}A and [4](#dom13261-fig-0004){ref-type="fig"}A and Table S3 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}). In patients with differing duration of diabetes, IDegAsp twice daily was also associated with significantly lower rates of confirmed hypoglycaemia (*P* \< .01; Figure [3](#dom13261-fig-0003){ref-type="fig"}B) and nocturnal confirmed hypoglycaemia (*P* \< .0001; Figure [4](#dom13261-fig-0004){ref-type="fig"}B) vs comparators, with rate ratios for those with diabetes for ≤10 and \>10 years of 0.61 and 0.76 for confirmed hypoglycaemia, and 0.31 and 0.48 for nocturnal confirmed hypoglycaemia, respectively. Likewise, regardless of baseline BMI, IDegAsp twice daily was associated with lower rates of confirmed hypoglycaemia (Figure [3](#dom13261-fig-0003){ref-type="fig"}C) and nocturnal confirmed hypoglycaemia (Figure [4](#dom13261-fig-0004){ref-type="fig"}C) than comparators; rate ratios for ≤30 and \>30 kg/m^2^ were 0.81 (*P* = .0288) and 0.55 (*P* \< .0001) for confirmed hypoglycaemia and 0.43 (*P* \< .0001) and 0.38 (*P* \< .0001) for nocturnal confirmed hypoglycaemia, respectively. As the rate of severe hypoglycaemia was low in both IDegAsp (0‐0.87 events per 100 patient‐years of exposure) and comparator groups (0‐1.15 events per 100 patient‐years of exposure), meaningful comparisons were not possible and therefore these data are not presented.

![Rate ratios and 95% confidence intervals (CIs) for confirmed hypoglycaemia (per 100 patient‐years of exposure) stratified by: A, glycated haemoglobin (HbA1c) category (mmol/mol); B, diabetes duration (years); and C, body mass index (BMI, kg/m^2^). Data are rate ratios, insulin degludec/insulin aspart (IDegAsp) vs comparator (95% CI), and are from the full analysis set, LOCF. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .0001. Comparator: biphasic insulin aspart 30 (BIAsp 30; NCT01009580, NCT01059812, NCT01513590), insulin degludec (IDeg) once daily + insulin aspart (IAsp; NCT01713530). Trial NCT01680341: IDegAsp Simple and IDegAsp Step‐wise arms are considered within the IDegAsp group. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or has a recorded plasma glucose \<3.1 mmol/L (56 mg/dL)](DOM-20-1585-g002){#dom13261-fig-0003}

![Rate ratios and 95% confidence intervals (CIs) for nocturnal confirmed hypoglycaemia (per 100 patient‐years of exposure) stratified by: A, glycated haemoglobin (HbA1c) category (mmol/mol); B, diabetes duration (years); and C, body mass index (BMI, kg/m^2^). Data are rate ratios, insulin degludec/insulin aspart (IDegAsp) vs comparator (95% CI), and are from the full analysis set, LOCF. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .0001. Comparators: biphasic insulin aspart 30 (BIAsp 30; NCT01009580, NCT01059812, NCT01513590), insulin degludec (IDeg) once daily + insulin aspart (IAsp; NCT01713530). Trial NCT01680341: IDegAsp Simple and IDegAsp Step‐wise arms are considered within the IDegAsp group. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or has a recorded plasma glucose \<3.1 mmol/L (56 mg/dL). Nocturnal period: the period between 12:01 [am]{.smallcaps} and 5:59 [am]{.smallcaps} (both inclusive)](DOM-20-1585-g001){#dom13261-fig-0004}

3.5. Insulin dose {#dom13261-sec-0013}
-----------------

The EOT daily insulin dose (Figure S3 and Table S4 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}) was numerically lower with IDegAsp twice daily vs comparators in all baseline HbA1c, diabetes duration and BMI categories, reaching statistical significance in patients with baseline HbA1c of 53.0 to \<58.5 mmol/mol (*P* \< .01) and ≥58.5‐\<69.4 mmol/mol (*P* \< .05; Figure S3A and Table S4 in [File S1](#dom13261-supitem-0001){ref-type="supplementary-material"}), diabetes duration of \>10 years (*P* \< .0001) and baseline BMI of ≤30 kg/m^2^ (*P* \< .0001). Similar differences were found when comparing EOT daily insulin doses for IDegAsp vs BIAsp 30, while EOT daily insulin doses were significantly lower in those with baseline HbA1c ≥58.5 to \<69.4 mmol/mol vs IDeg once daily + IAsp (*P* \< .05; data not shown).

4. DISCUSSION {#dom13261-sec-0014}
=============

This post hoc pooled analysis of 5 phase III randomized trials found that IDegAsp compares favourably across all baseline criteria (BMI, duration of diabetes and glycaemic control) when compared with the comparators in the pooled population (BIAsp 30 twice daily or IDeg once daily + IAsp \[2‐4 injections\]) in terms of safety and efficacy. In terms of glycaemic efficacy, IDegAsp compared favourably with these comparators; no differences were observed in EOT HbA1c (across all baseline groups), and EOT FPG levels were significantly lower in patients using IDegAsp vs comparators in all but 1 category (baseline FPG \<5.5 mmol/L) when stratified by baseline FPG, diabetes duration and BMI. These findings are in broad agreement with those of the total population from the individual treat‐to‐target phase III trials comparing IDegAsp with BIAsp 30 twice daily or IDeg once daily + IAsp. In addition, the safety results in the present study echo those of the individual trials, showing significantly lower rates of hypoglycaemia with IDegAsp than with comparators.[27](#dom13261-bib-0027){ref-type="ref"}, [28](#dom13261-bib-0028){ref-type="ref"}, [29](#dom13261-bib-0029){ref-type="ref"}, [30](#dom13261-bib-0030){ref-type="ref"}, [31](#dom13261-bib-0031){ref-type="ref"} IDegAsp twice daily was associated with lower rates of confirmed and nocturnal confirmed hypoglycaemia vs comparators, independently of baseline HbA1c, duration of diabetes and baseline BMI. As demonstrated previously, rates of hypoglycaemia were higher in those with a lower BMI (\<30 kg/m^2^) and longer duration of diabetes, with no apparent association between baseline HbA1c and rates of hypoglycaemia.[34](#dom13261-bib-0034){ref-type="ref"} Notably, EOT insulin dose was significantly lower in patients on IDegAsp with baseline HbA1c 53.0 to \<58.5 mmol/mol and ≥58.5‐\<69.4 mmol/mol, diabetes duration \>10 years or BMI ≤30 kg/m^2^. The latter 2 findings (diabetes duration and BMI) may be influenced by the results from INTENSIFY ALL, which compared IDegAsp with BIAsp 30 in Asian patients with a longer duration of diabetes and lower BMI compared with the other phase III trials.

These positive results (similar HbA1c levels, lower EOT FPG levels and lower rates of confirmed and nocturnal hypoglycaemia with IDegAsp vs comparators) are consistent with the results from the BEGIN trials[35](#dom13261-bib-0035){ref-type="ref"}, [36](#dom13261-bib-0036){ref-type="ref"}, [37](#dom13261-bib-0037){ref-type="ref"}, [38](#dom13261-bib-0038){ref-type="ref"}, [39](#dom13261-bib-0039){ref-type="ref"} of IDeg (both comparing IDeg and IGlar) and may be largely attributed to the actions of IDeg in the IDegAsp formulation (ie, lower variability and a longer duration of action compared with the 70% protamine crystallized IAsp in BIAsp 30).[21](#dom13261-bib-0021){ref-type="ref"}, [25](#dom13261-bib-0025){ref-type="ref"} This shows that the actions of IDeg are clearly preserved in the IDegAsp co‐formulation, and thus the lower rates of hypoglycaemia (vs comparators such as BIAsp 30) may give clinicians greater confidence to prescribe doses at which lower HbA1c targets are more likely to be achieved. Furthermore, the dual benefits of having simplified diabetes management (basal and prandial glycaemic control in a single injection) with less weight gain, may also lead to improved patient adherence and outcomes.[40](#dom13261-bib-0040){ref-type="ref"}

In summary, the findings of this pooled analysis show that IDegAsp is an effective treatment across a spectrum of patient baseline characteristics (HbA1c, duration of diabetes and BMI). Further, these findings support the use of IDegAsp to address the clinical need to improve patient adherence and outcomes by providing a simpler treatment, with lower rates of hypoglycaemia, at a similar dose with no excess weight gain when compared with a mixed population of patients treated with BIAsp 30 and IDeg + IAsp.

The limitations of the present pooled analysis stem partly from its constituent studies, such as the inclusion of open‐label studies, variability in study design and study duration of \<1 year, which limits our conclusions to the short term. To be able to draw conclusions from the subgroups of the individual trials, data were pooled from the studies comparing IDegAsp twice daily with BIAsp 30 twice daily and IDeg + IAsp once daily. In addition, the patient population in the INTENSIFY ALL trial differed from the other phase III trials, and its Asian population of patients had a lower mean BMI and longer duration of diabetes compared with patients in the other phase III trials, potentially influencing the results.

In conclusion, this pooled analysis shows that IDegAsp retains the efficacy and safety benefits shown in the phase III studies when compared with either basal--bolus or premixed insulin among a wide range of patients with T2D with different baseline characteristics. This finding gives confidence to prescribers that IDegAsp is a reliable option for patients with T2D in need of insulin intensification.

Supporting information
======================

###### 

**Figure S1** Mean age by disease duration (years).

**Figure S2** Body weight (kg) EOT by baseline BMI (kg/m^2^).

**Figure S3** Total daily insulin dose (U) at EOT, stratified by: A, HbA1c categories (%); B, diabetes duration (years); and c) BMI (kg/m^2^).
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Prof. Jens Sandahl Christiansen, who was an investigator in the present study, died whilst the manuscript was in preparation. His contribution to the work is noted here, as is the very significant contribution he made to the field of endocrinology and the diabetes community. His positive attitude, enthusiasm and kindness will be remembered by all those who had the opportunity to work with him.
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